Reviewing NanoVibronix (NAOV) and Its Competitors

NanoVibronix (NASDAQ: NAOV) is one of 28 public companies in the “Surgical appliances & supplies” industry, but how does it compare to its rivals? We will compare NanoVibronix to related businesses based on the strength of its earnings, dividends, profitability, risk, valuation, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares NanoVibronix and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
NanoVibronix $240,000.00 -$4.96 million -2.91
NanoVibronix Competitors $1.35 billion $134.43 million 17.37

NanoVibronix’s rivals have higher revenue and earnings than NanoVibronix. NanoVibronix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

14.2% of NanoVibronix shares are held by institutional investors. Comparatively, 58.3% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 18.7% of NanoVibronix shares are held by insiders. Comparatively, 9.5% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for NanoVibronix and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NanoVibronix 0 0 1 0 3.00
NanoVibronix Competitors 203 891 1526 76 2.55

As a group, “Surgical appliances & supplies” companies have a potential upside of 16.63%. Given NanoVibronix’s rivals higher possible upside, analysts clearly believe NanoVibronix has less favorable growth aspects than its rivals.

Volatility and Risk

NanoVibronix has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500. Comparatively, NanoVibronix’s rivals have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.

Profitability

This table compares NanoVibronix and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NanoVibronix -1,380.78% -180.81% -127.54%
NanoVibronix Competitors -153.41% -191.82% -24.90%

Summary

NanoVibronix rivals beat NanoVibronix on 9 of the 13 factors compared.

About NanoVibronix

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.

Receive News & Ratings for NanoVibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoVibronix and related companies with MarketBeat.com's FREE daily email newsletter.